Mu opioid splice variant MOR-1K contributes to the development of opioid-induced hyperalgesia

26Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Background: A subset of the population receiving opioids for the treatment of acute and chronic clinical pain develops a paradoxical increase in pain sensitivity known as opioid-induced hyperalgesia. Given that opioid analgesics are one of few treatments available against clinical pain, it is critical to determine the key molecular mechanisms that drive opioid-induced hyperalgesia in order to reduce its prevalence. Recent evidence implicates a splice variant of the mu opioid receptor known as MOR-1K in the emergence of opioid-induced hyperalgesia. Results from human genetic association and cell signaling studies demonstrate that MOR-1K contributes to decreased opioid analgesic responses and produces increased cellular activity via Gssignaling. Here, we conducted the first study to directly test the role of MOR-1K in opioid-induced hyperalgesia. Methods and Results: In order to examine the role of MOR-1K in opioid-induced hyperalgesia, we first assessed pain responses to mechanical and thermal stimuli prior to, during, and following chronic morphine administration. Results show that genetically diverse mouse strains (C57BL/6J, 129S6, and CXB7/ByJ) exhibited different morphine response profiles with corresponding changes in MOR-1Kgene expression patterns. The 129S6 mice exhibited an analgesic response correlating to a measured decrease in MOR-1Kgene expression levels, while CXB7/ByJ mice exhibited a hyperalgesic response correlating to a measured increase in MOR-1Kgene expression levels. Furthermore, knockdown of MOR-1Kin CXB7/ByJ mice via chronic intrathecal siRNA administration not only prevented the development of opioid-induced hyperalgesia, but also unmasked morphine analgesia. Conclusions: These findings suggest that MOR-1K is likely a necessary contributor to the development of opioid-induced hyperalgesia. With further research, MOR-1K could be exploited as a target for antagonists that reduce or prevent opioid-induced hyperalgesia. Copyright:

Cite

CITATION STYLE

APA

Oladosu, F. A., Conrad, M. S., O’Buckley, S. C., Rashid, N. U., Slade, G. D., & Nackley, A. G. (2015). Mu opioid splice variant MOR-1K contributes to the development of opioid-induced hyperalgesia. PLoS ONE, 10(8). https://doi.org/10.1371/journal.pone.0135711

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free